Evaluating the effect of bumetanide on ALS

Evaluating the effect of bometanide on spasticity in patients with ALS

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201020049089N1

Enrollment

Registered

2020-12-15

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis

Interventions

Intervention 1: Intervention group: In this group, ALS patients will be treated with bometanid at a dose of 2 mg every 12 hours as an oral tablet for 3 months. Intervention 2: Control group: In this g

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. No history of other neurological diseases such as stroke and dementia 2. No orthopedic problems 3. Not having diabetes. addiction. hepatitis 4. The patient's education level at least up to the fifth grade

Exclusion criteria

Exclusion criteria: 1. Lack of cooperation of the patient during testing and exercises 2. Failure to refer the patient for the second stage tests after the interventions 3. Patients whose diet is changed.

Design outcomes

Primary

Measure	Time frame
MUNIX and ALSFRS-R. Timepoint: Before and after intervention. Method of measurement: ALSFRS-R questionnaire and electromyogram device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Taghi Jogharaei

Iran University of Medical Sciences

mt.joghataei@yahoo.com86704837

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026